导管相关血流感染疾病市场 - 全球产业规模、份额、趋势、机会及预测（按治疗类型、感染来源、分销管道、地区和竞争格局划分，2021-2031年）

全球导管相关血流感染市场预计将从 2025 年的 16.2 亿美元成长到 2031 年的 22.5 亿美元，复合年增长率为 5.63%。

该市场涵盖多种感染预防和治疗解决方案，包括抗菌导管、抗生素封管液和固定装置，旨在降低与血管通路相关的病原体感染风险。推动这一增长的关键因素包括需要长期住院治疗的慢性病患者人数增加，以及老年人口不断增长（老年人感染医院感染的风险更高）。此外，严格的监管要求（对可预防感染率高的医疗机构进行处罚）也促使医疗机构采用专业的消毒和导管插入技术。

然而，与标准导管相比，高端抗菌导管由于高成本，面临着许多障碍，这限制了其在预算紧张的医疗机构中的应用。此外，严格的报销政策要求医疗机构承担医院感染的治疗费用，进一步加剧了这种障碍。国际医院感染控制联盟（INICC）的报告凸显了对有效解决方案的持续高临床需求：2024年，儿童重症监护患者中央静脉导管相关血流感染的汇总平均发生率为每1000导管日5.37例。

市场驱动因素

新型导管封管液和治疗方法的引入，为生理食盐水和肝素冲洗提供了更先进的替代方案，从而对市场产生了决定性的影响，尤其满足了在不移除感染导管的情况下挽救导管的临床需求。随着医疗机构寻求降低中央静脉导管更换相关併发症风险和操作复杂性，这些创新治疗方法正日益受到关注。这些新一代解决方案的有效性正在重塑治疗通讯协定。根据Citius Pharmaceuticals于2024年5月发布的公告，一项Minoloc抗菌封管液的III期临床研究显示，在导管相关血流感染患者中，整体治疗成功率为57.1%，而对照组为37.7%。这些结果支持转向更高价值的药物介入措施。

严格的感染控制措施是重要的监管力量，迫使医院投资全面的预防措施和监测技术，以避免受到处罚。监管机构越来越多地将报销与安全绩效挂钩，从而推动标准化导管护理通讯协定和先进固定装置的采用。儘管Leapfrog Group在2024年11月发布的全国数据显示，自2022年秋季以来，中央静脉导管相关血流感染的平均分数下降了38%，但合规也带来了成本压力。例如，CorMedix新核准的抗菌导管封管液的批发采购价为管瓶249.99美元，这显示实施这些安全措施需要大量的资金投入。

市场挑战

全球导管相关血流感染市场面临一个显着的障碍，那就是高阶抗菌导管的价格远高于标准静脉通路装置。虽然这些先进的解决方案能够更好地抵御病原体，但其高昂的价格对预算紧张的医疗机构构成了重大障碍。此外，现行的健保报销机制也加剧了这一困境：医院感染的惩罚力道很大，而主动预防性技术却往往得不到足够的资金支持。因此，注重成本的采购部门通常会选择标准导管，这些导管需要严格且耗时的消毒通讯协定才能符合监管安全标准，而不是选择昂贵的抗菌导管。

这种采购行为限制了高利润抗菌产品的采用，从而直接抑制了市场收入成长。医疗机构如果仅透过流程改善和遵循标准控制措施就能达到所需的安全效果，则可能无需采用昂贵的创新技术。例如，Leapfrog Group 在 2024 年发布的报告显示，受访医院在过去两年中央静脉导管相关血流感染率下降了 38%，这反映了这些替代感染控制策略的有效性。这表明，医疗机构目前采用的控制措施能够有效控制感染率，从而可能减少对高成本导管技术的商业性投资需求。

市场趋势

随着感染预防解决方案在医疗保健领域的应用日益广泛，市场动态也随之重塑，医疗服务模式正从急性医院转向门诊和居家照护。这项转变源自于降低长期住院成本和最大限度减少医院感染风险的临床需求，显着提升了对优化静脉通路装置和非临床用户无菌产品的需求。因此，输液服务供应商正经历显着成长。 2025年10月，Option Care Health在第三季公布财报上宣布，公司收入净额达14.35亿美元，年增12.2%，主要得益于输液治疗加速居家环境转移。

同时，人工智慧驱动的数位监测和数据分析正成为变革性力量，使医疗机构能够自动检测导管相关病原体。透过将机器学习演算法与电子健康记录集成，医疗机构可以快速识别感染丛集，简化报告流程，并显着减轻感染防治负责人的行政负担。这项技术整合提高了诊断准确性，并缩短了审核时间。牛津学术出版社2025年11月的一项研究发现，人工智慧辅助的监测审核平均每个病例耗时14分钟，而专家审查则需要25分钟，这表明演算法监测显着提高了效率。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球导管相关血流感染疾病市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依治疗类型（抗菌药物、抗生素封管疗法）
  • 依感染源分类（凝固酶阴性葡萄球菌、金黄色葡萄球菌、肠道革兰氏阴性桿菌、酵母菌、肠球菌和链球菌、绿脓桿菌、其他）
  • 按分销管道（医院药房、零售药房、网路药房）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美导管相关血流感染疾病市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲导管相关血流感染疾病市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区导管相关血流感染疾病市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲导管相关血流感染疾病市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美导管相关血流感染疾病市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

13. 全球导管相关血流感染疾病市场：SWOT 分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Teva Pharmaceutical Industries Ltd.
• SteriMax Inc.
• Sanofi SA
• Pfizer Inc.
• Novartis AG
• Merck & Co., Inc.
• GSK plc
• Fresenius SE & Co. KGaA
• Eli Lilly and Company
• Aurobindo Pharma Limited

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Catheter Related Bloodstream Infection Market is projected to expand from USD 1.62 Billion in 2025 to USD 2.25 Billion by 2031, reflecting a compound annual growth rate of 5.63%. This market encompasses a range of infection prevention and treatment solutions, including antimicrobial catheters, antibiotic locks, and site securement devices, all designed to mitigate pathogen risks associated with vascular access. The primary forces driving this growth include the increasing prevalence of chronic diseases necessitating prolonged hospitalization and a growing geriatric population vulnerable to hospital-acquired conditions. Additionally, strict regulatory mandates that penalize healthcare facilities for preventable infection rates are compelling the adoption of specialized sterilization and catheter technologies.

However, the market encounters significant obstacles due to the high cost of premium antimicrobial catheters compared to standard options, which restricts their adoption in budget-constrained healthcare settings. This barrier is exacerbated by rigorous reimbursement policies that hold medical facilities financially responsible for treating hospital-acquired infections. Underscoring the continued clinical necessity for effective solutions, the International Nosocomial Infection Control Consortium reported in 2024 that the pooled mean central line-associated bloodstream infection rate among pediatric intensive care patients was 5.37 episodes per 1,000 catheter days.

Market Driver

The introduction of novel catheter lock solutions and therapies is critically influencing the market by offering advanced alternatives to traditional saline or heparin flushes, specifically addressing the clinical need to salvage infected devices rather than removing them. These innovative therapies are gaining traction as healthcare providers seek to reduce the morbidity and logistical complexity associated with central venous catheter replacement. The efficacy of these next-generation solutions is reshaping treatment protocols; according to Citius Pharmaceuticals in May 2024, the Phase 3 Trial of Mino-Lok Antibiotic Lock Solution demonstrated an overall treatment success rate of 57.1% in patients with catheter-related bloodstream infections compared to 37.7% in the control arm, validating the shift toward high-value pharmacological interventions.

The implementation of stringent infection control mandates serves as a primary regulatory force, pushing hospitals to invest in comprehensive prevention bundles and surveillance technologies to avoid financial penalties. Regulatory bodies are increasingly linking reimbursement to safety performance, driving the adoption of standardized catheter care protocols and advanced securement devices. While recent national data from The Leapfrog Group in November 2024 indicates that average central line-associated bloodstream infection scores decreased by 38% since the fall of 2022, compliance brings cost pressures; for instance, CorMedix Inc. established a wholesale acquisition cost of $249.99 per vial for its newly approved antimicrobial catheter lock solution in 2024, illustrating the significant financial investment required to integrate these safeguards.

Market Challenge

The Global Catheter Related Bloodstream Infection Market faces a distinct obstacle regarding the prohibitive cost of premium antimicrobial catheters compared to standard vascular access devices. While these advanced solutions offer enhanced pathogen protection, their elevated price creates a significant barrier for healthcare facilities managing restricted budgets, a friction intensified by reimbursement structures that impose strict penalties for hospital-acquired conditions but often fail to provide adequate funding for upfront preventative technologies. Consequently, cost-sensitive procurement departments frequently opt for standard catheters, substituting expensive device-based solutions with rigorous, labor-intensive sterility protocols to meet regulatory safety standards.

This purchasing behavior directly restricts market revenue growth by limiting the adoption volume of high-margin antimicrobial products. Medical facilities may bypass expensive innovations if they can achieve required safety outcomes through process improvements and standard bundle compliance alone. Highlighting the effectiveness of these alternative containment strategies, The Leapfrog Group noted in 2024 that central line-associated bloodstream infections decreased by 38% over the last two years across surveyed hospitals, suggesting that facilities are effectively controlling infection rates through current measures, potentially diminishing the perceived commercial necessity for investing in higher-cost catheter technologies.

Market Trends

The expansion of infection prevention solutions into home healthcare settings is reshaping market dynamics as care delivery shifts from acute hospital environments to ambulatory and domiciliary models. This transition is driven by the clinical necessity to reduce long-term hospitalization costs and minimize nosocomial exposure, fostering high demand for vascular access devices and sterility products optimized for non-clinical users. Consequently, infusion service providers are witnessing substantial growth; according to Option Care Health in October 2025, the company reported net revenue of $1.435 billion in its third-quarter earnings call, representing a 12.2% increase over the prior year due to the accelerated migration of infusion therapies to the home setting.

Simultaneously, the utilization of AI-driven digital surveillance and data analytics is emerging as a transformative force, enabling healthcare facilities to automate the complex detection of catheter-related pathogens. By integrating machine learning algorithms with electronic health records, institutions can rapidly identify infection clusters and streamline reporting compliance, significantly reducing the administrative burden on infection preventionists. This technological integration enhances diagnostic accuracy and cuts review time; according to Oxford Academic in November 2025, AI-assisted surveillance review required a median of 14 minutes per case compared to 25 minutes for expert review, demonstrating significant efficiency gains through algorithmic monitoring.

Key Market Players

• Teva Pharmaceutical Industries Ltd.
• SteriMax Inc.
• Sanofi S.A.
• Pfizer Inc.
• Novartis AG
• Merck & Co., Inc.
• GSK plc
• Fresenius SE & Co. KGaA
• Eli Lilly and Company
• Aurobindo Pharma Limited

Report Scope

In this report, the Global Catheter Related Bloodstream Infection Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Catheter Related Bloodstream Infection Market, By Treatment Type

• Anti-microbial Agents
• Antibiotic Lock Therapy

Catheter Related Bloodstream Infection Market, By Source of Infection

• Coagulase-negative Staphylococcus
• S. Aureus
• Enteric Gram-negative Bacilli
• Yeasts
• Enterococci & Streptococci
• Pseudomonas
• Others

Catheter Related Bloodstream Infection Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Catheter Related Bloodstream Infection Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Catheter Related Bloodstream Infection Market.

Available Customizations:

Global Catheter Related Bloodstream Infection Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Catheter Related Bloodstream Infection Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type (Anti-microbial Agents, Antibiotic Lock Therapy)
  • 5.2.2. By Source of Infection (Coagulase-negative Staphylococcus, S. Aureus, Enteric Gram-negative Bacilli, Yeasts, Enterococci & Streptococci, Pseudomonas, Others)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Catheter Related Bloodstream Infection Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By Source of Infection
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Catheter Related Bloodstream Infection Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By Source of Infection
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Catheter Related Bloodstream Infection Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By Source of Infection
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Catheter Related Bloodstream Infection Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By Source of Infection
      • 6.3.3.2.3. By Distribution Channel

7. Europe Catheter Related Bloodstream Infection Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By Source of Infection
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Catheter Related Bloodstream Infection Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By Source of Infection
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Catheter Related Bloodstream Infection Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By Source of Infection
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Catheter Related Bloodstream Infection Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By Source of Infection
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Catheter Related Bloodstream Infection Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment Type
      • 7.3.4.2.2. By Source of Infection
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Catheter Related Bloodstream Infection Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment Type
      • 7.3.5.2.2. By Source of Infection
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Catheter Related Bloodstream Infection Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By Source of Infection
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Catheter Related Bloodstream Infection Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By Source of Infection
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Catheter Related Bloodstream Infection Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By Source of Infection
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Catheter Related Bloodstream Infection Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By Source of Infection
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Catheter Related Bloodstream Infection Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment Type
      • 8.3.4.2.2. By Source of Infection
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Catheter Related Bloodstream Infection Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment Type
      • 8.3.5.2.2. By Source of Infection
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Catheter Related Bloodstream Infection Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By Source of Infection
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Catheter Related Bloodstream Infection Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By Source of Infection
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Catheter Related Bloodstream Infection Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By Source of Infection
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Catheter Related Bloodstream Infection Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By Source of Infection
      • 9.3.3.2.3. By Distribution Channel

10. South America Catheter Related Bloodstream Infection Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By Source of Infection
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Catheter Related Bloodstream Infection Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By Source of Infection
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Catheter Related Bloodstream Infection Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By Source of Infection
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Catheter Related Bloodstream Infection Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By Source of Infection
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Catheter Related Bloodstream Infection Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Teva Pharmaceutical Industries Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. SteriMax Inc.
• 15.3. Sanofi S.A.
• 15.4. Pfizer Inc.
• 15.5. Novartis AG
• 15.6. Merck & Co., Inc.
• 15.7. GSK plc
• 15.8. Fresenius SE & Co. KGaA
• 15.9. Eli Lilly and Company
• 15.10. Aurobindo Pharma Limited

16. Strategic Recommendations

17. About Us & Disclaimer